{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:31:33Z","timestamp":1771327893701,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s11894-006-0067-8","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:41:34Z","timestamp":1180060894000},"page":"75-82","source":"Crossref","is-referenced-by-count":45,"title":["Primary sclerosing cholangitis: Diagnosis and management"],"prefix":"10.1007","volume":"8","author":[{"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"67_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","volume":"33","author":"KM Boberg","year":"1998","unstructured":"Boberg KM, Aadland E, Jahnsen J, et al.: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99\u2013103.","journal-title":"Scand J Gastroenterol"},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","volume":"125","author":"K Bambha","year":"2003","unstructured":"Bambha K, Kim WR, Talwalkar J, et al.: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364\u20131369.","journal-title":"Gastroenterology"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2004.04.052","volume":"126","author":"JG Kingham","year":"2004","unstructured":"Kingham JG, Kochar N, Gravenor MB: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126:1929\u20131930.","journal-title":"Gastroenterology"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2004.10.011","volume":"42","author":"A Bergquist","year":"2005","unstructured":"Bergquist A, Lindberg G, Saarinen S, et al.: Increased prevalence of primary sclerosing cholangitis among firstdegree relatives. J Hepatol 2005, 42:252\u2013256. These data support the hypothesis that genetic factors are important for development of PSC.","journal-title":"J Hepatol"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2005.02328.x","volume":"21","author":"A Lawson","year":"2005","unstructured":"Lawson A, West J, Aithal GP, et al.: Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association. Aliment Pharmacol Ther 2005, 21:401\u2013405.","journal-title":"Aliment Pharmacol Ther"},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00054725-200501000-00009","volume":"11","author":"JA Talwalkar","year":"2005","unstructured":"Talwalkar JA, Lindor KD: Primary sclerosing cholangitis. Inflamm Bowel Dis 2005, 11:62\u201372.","journal-title":"Inflamm Bowel Dis"},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2004.09.003","volume":"4","author":"CA Aoki","year":"2005","unstructured":"Aoki CA, Bowlus CL, Gershwin ME: The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005, 4:137\u2013143.","journal-title":"Autoimmun Rev"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/jhep.2003.50289","volume":"38","author":"AE Feldstein","year":"2003","unstructured":"Feldstein AE, Perrault J, El-Youssif M, et al.: Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003, 38:210\u2013217.","journal-title":"Hepatology"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5107(04)02229-1","volume":"60","author":"T Nakazawa","year":"2004","unstructured":"Nakazawa T, Ohara H, Sano H, et al.: Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004, 60:937\u2013944.","journal-title":"Gastrointest Endosc"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/00004728-200211000-00024","volume":"26","author":"D Resnick","year":"2002","unstructured":"Resnick D, Krinsky GA, Lavelle MT, et al.: Do patients with primary sclerosing cholangitis have a greater frequency of pancreatic abnormalities at MRI than patients with other liver diseases? J Comput Assist Tomogr 2002, 26:994\u2013999.","journal-title":"J Comput Assist Tomogr"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0168-8278(00)80002-1","volume":"33","author":"P Angulo","year":"2000","unstructured":"Angulo P, Pearce DH, Johnson CD, et al.: Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000, 33:520\u2013527.","journal-title":"J Hepatol"},{"key":"67_CR12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1055\/s-2002-35830","volume":"34","author":"HJ Textor","year":"2002","unstructured":"Textor HJ, Flacke S, Pauleit D, et al.: Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002, 34:984\u2013990.","journal-title":"Endoscopy"},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.20287","volume":"40","author":"JA Talwalkar","year":"2004","unstructured":"Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39\u201345.","journal-title":"Hepatology"},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1148\/rg.243035087","volume":"24","author":"AC Silva","year":"2004","unstructured":"Silva AC, Friese JL, Hara AK, et al.: MR cholangiopancreatography: improved ductal distention with intravenous morphine administration. Radiographics 2004, 24:677\u2013687.","journal-title":"Radiographics"},{"key":"67_CR15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.dld.2004.03.018","volume":"36","author":"V Macchi","year":"2004","unstructured":"Macchi V, Floreani A, Marchesi P, et al.: Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 2004, 36:614\u2013621.","journal-title":"Dig Liver Dis"},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00384-004-0598-0","volume":"19","author":"TO Hirche","year":"2004","unstructured":"Hirche TO, Russler J, Braden B, et al.: Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis 2004, 19:586\u2013594.","journal-title":"Int J Colorectal Dis"},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1572-0241.2003.07401.x","volume":"98","author":"KW Burak","year":"2003","unstructured":"Burak KW, Angulo P, Lindor KD: Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003, 98:1155\u20131158.","journal-title":"Am J Gastroenterol"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","volume":"35","author":"P Angulo","year":"2002","unstructured":"Angulo P, Maor-Kendler Y, Lindor KD: Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002, 35:1494\u20131500.","journal-title":"Hepatology"},{"key":"67_CR19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.51.5.731","volume":"51","author":"E Bjornsson","year":"2002","unstructured":"Bjornsson E, Boberg KM, Cullen S, et al.: Patients with small duct primary sclerosing cholangitis have a favorable long term prognosis. Gut 2002, 51:731\u2013735.","journal-title":"Gut"},{"key":"67_CR20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0168-8278(00)80004-5","volume":"33","author":"M Kaya","year":"2000","unstructured":"Kaya M, Angulo P, Lindor KD: Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537\u201342.","journal-title":"J Hepatol"},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00042737-200406000-00012","volume":"16","author":"L Gheorghe","year":"2004","unstructured":"GheorgheL, Iacob S, Gheorghe C, et al.: Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004, 16:585\u2013592. These authors identified the independent predictive factors associated with the diagnosis of overlap syndrome, which were young age, ANA seronegativity, and probable diagnosis according to the scoring system for AIH.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"67_CR22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","volume":"100","author":"A Floreani","year":"2005","unstructured":"Floreani A, Rizzotto ER, Ferrara F, et al.: Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516\u20131522.","journal-title":"Am J Gastroenterol"},{"key":"67_CR23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.20029","volume":"39","author":"CO Zein","year":"2004","unstructured":"Zein CO, Lindor KD, Angulo P: Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004, 39:204\u2013210.","journal-title":"Hepatology"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00365520410003434","volume":"39","author":"E Bjornsson","year":"2004","unstructured":"Bjornsson E, Simren M, Olsson R, et al.: Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004, 39:961\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-4-13","volume":"4","author":"PC Borg ter","year":"2004","unstructured":"ter Borg PC, van Os E, van den Broek WW, et al.: Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004, 4:1\u201313.","journal-title":"BMC Gastroenterol"},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:DDAS.0000011827.87103.2e","volume":"49","author":"MP Epstein","year":"2004","unstructured":"Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1\u20134.","journal-title":"Dig Dis Sci"},{"key":"67_CR27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1478-3231.2005.01075.x","volume":"25","author":"MS Campbell","year":"2005","unstructured":"Campbell MS, Lichtenstein GR, Rhim AD, et al.: Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int 2005, 25:311\u2013316.","journal-title":"Liver Int"},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1572-0241.2001.03690.x","volume":"96","author":"M Kaya","year":"2001","unstructured":"Kaya M, Petersen BT, Angulo P, et al.: Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059\u20131066.","journal-title":"Am J Gastroenterol"},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","volume":"99","author":"E Bjornsson","year":"2004","unstructured":"Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al.: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:502\u2013508. This study demonstrated that cholestasis in patients with PSC does not seem to be related to the presence of dominant stricture, and that endoscopic therapy should not be routinely undertaken.","journal-title":"Am J Gastroenterol"},{"key":"67_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","volume":"36","author":"A Stiehl","year":"2002","unstructured":"Stiehl A, Rudolph G, Kloters-Plachky P, et al.: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002, 36:151\u2013156.","journal-title":"J Hepatol"},{"key":"67_CR31","doi-asserted-by":"crossref","first-page":"AB193","DOI":"10.1016\/S0016-5107(04)00900-9","volume":"59","author":"SK Vuddagiri","year":"2004","unstructured":"Vuddagiri SK, France R, Kozarek R: Endoscopic therapy in primary sclerosing cholangitis (PSC): does the complication risk outweigh therapeutic benefit? [abstract]. Gastrointest Endosc 2004: 59:AB193.","journal-title":"Gastrointest Endosc"},{"key":"67_CR32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","volume":"99","author":"K Burak","year":"2004","unstructured":"Burak K, Angulo P, Pasha TM, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523\u2013526.","journal-title":"Am J Gastroenterol"},{"key":"67_CR33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","volume":"40","author":"B Brandsaeter","year":"2004","unstructured":"BrandsaeterB, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis, predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815\u2013822. This prospective study sought to determine predictors of hepatobiliary malignancy in PSC patients listed for liver transplantation that might add to our knowledge on how to handle these patients.","journal-title":"J Hepatol"},{"key":"67_CR34","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","volume":"50","author":"C Levy","year":"2005","unstructured":"Levy C, Lymp J, Angulo P, et al.: The value of serum CA 19\u20139 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734\u20131740.","journal-title":"Dig Dis Sci"},{"key":"67_CR35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1055\/s-2002-35298","volume":"34","author":"B Lindberg","year":"2002","unstructured":"Lindberg B, Arnelo U, Bergquist A, et al.: Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002, 34:909\u2013916.","journal-title":"Endoscopy"},{"key":"67_CR36","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.20469","volume":"101","author":"J Koopmann","year":"2004","unstructured":"Koopmann J, Thuluvath PJ, Zahurak ML, et al.: Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004, 101:1609\u20131615.","journal-title":"Cancer"},{"key":"67_CR37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-2004-828894","volume":"24","author":"F Berr","year":"2004","unstructured":"Berr F: Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 2004, 24:177\u2013187.","journal-title":"Semin Liver Dis"},{"key":"67_CR38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2004-828893","volume":"24","author":"EM Abu-Hamda","year":"2004","unstructured":"Abu-Hamda EM, Baron TH: Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004, 24:165\u2013175.","journal-title":"Semin Liver Dis"},{"key":"67_CR39","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1572-0241.2002.05677.x","volume":"97","author":"DC Buckles","year":"2002","unstructured":"Buckles DC, Lindor KD, Larusso NF, et al.: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002, 97:1138\u20131142.","journal-title":"Am J Gastroenterol"},{"key":"67_CR40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","volume":"54","author":"EV Loftus Jr","year":"2005","unstructured":"Loftus EV Jr, Harewood GC, Loftus CG, et al.: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91\u201396. Based on the clinical features and outcomes of IBD associated with PSC, PSC-IBD may represent a distinct IBD phenotype.","journal-title":"Gut"},{"key":"67_CR41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","volume":"124","author":"DS Pardi","year":"2003","unstructured":"Pardi DS, Loftus EV Jr, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889\u2013893.","journal-title":"Gastroenterology"},{"key":"67_CR42","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10350-004-6655-5","volume":"46","author":"D Stahlberg","year":"2003","unstructured":"Stahlberg D, Veress B, Tribukait B, et al.: Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003, 46:770\u2013778.","journal-title":"Dis Colon Rectum"},{"key":"67_CR43","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.TP.0000058744.34965.38","volume":"75","author":"A Vera","year":"2003","unstructured":"Vera A, Gunson BK, Ussatoff V, et al.: Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003, 75:1983\u20131988.","journal-title":"Transplantation"},{"key":"67_CR44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","volume":"16","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Kruis W, et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707\u2013714.","journal-title":"Hepatology"},{"key":"67_CR45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","volume":"20","author":"A Stiehl","year":"1994","unstructured":"Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57\u201364.","journal-title":"J Hepatol"},{"key":"67_CR46","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"KD Lindor","year":"1997","unstructured":"Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691\u2013695.","journal-title":"N Engl J Med"},{"key":"67_CR47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","volume":"29","author":"HJ Hoogstraten van","year":"1998","unstructured":"van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al.: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29:417\u2013423.","journal-title":"J Hepatol"},{"key":"67_CR48","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hep.20370","volume":"40","author":"D Rost","year":"2004","unstructured":"Rost D, Rudolph G, Kloeters-Plachky P, et al.: Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693\u2013698. If biliary enrichment of UDCA represents the decisive factor for its clinical effect, this study demonstrated that biliary enrichment of UDCA increases with increasing dose and reaches a plateau at 22 to 25 mg\/kg with no increase of toxic hydrophobic bile acids.","journal-title":"Hepatology"},{"key":"67_CR49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900\u2013907.","journal-title":"Gastroenterology"},{"key":"67_CR50","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","volume":"96","author":"DM Harnois","year":"2001","unstructured":"Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558\u20131562.","journal-title":"Am J Gastroenterol"},{"key":"67_CR51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8278(04)90551-X","volume":"40","author":"RG Olsson","year":"2004","unstructured":"Olsson RG, Boberg KM, Schaffalitzky de Muckadel O, et al.: Five year treatment with high dose UDCA in PSC [abstract]. J Hepatol 2004, 40:161.","journal-title":"J Hepatol"},{"key":"67_CR52","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0016-5085(88)90180-1","volume":"95","author":"NF LaRusso","year":"1988","unstructured":"LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036\u20131042.","journal-title":"Gastroenterology"},{"key":"67_CR53","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","volume":"108","author":"R Olsson","year":"1995","unstructured":"Olsson R, Broome U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199\u20131203.","journal-title":"Gastroenterology"},{"key":"67_CR54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0016-5085(94)90610-6","volume":"106","author":"TA Knox","year":"1994","unstructured":"Knox TA, Kaplan MM: A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494\u2013499.","journal-title":"Gastroenterology"},{"key":"67_CR55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/gut.34.2.242","volume":"34","author":"WJ Sandborn","year":"1993","unstructured":"Sandborn WJ, Wiesner RH, Tremaine WJ, et al.: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993, 34:242\u2013246.","journal-title":"Gut"},{"key":"67_CR56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00042737-200102000-00013","volume":"13","author":"FP Vleggaar","year":"2001","unstructured":"Vleggaar FP, van Buuren HR, van Berge HenegouwenGP, et al.: No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001, 13:171\u2013175.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"67_CR57","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2000.02324.x","volume":"95","author":"AE Bharucha","year":"2000","unstructured":"Bharucha AE, Jorgensen R, Lichtman SN, et al.: A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2338\u20132342.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl.1","key":"67_CR58","doi-asserted-by":"crossref","first-page":"A353","DOI":"10.1016\/S0016-5085(01)81756-X","volume":"120","author":"P Angulo","year":"2001","unstructured":"Angulo P, Jorgensen R, Keach J, et al.: Silymarin in the treatment of patients with primary sclerosing cholangitis. Gastroenterology 2001, 120(Suppl.1):A353.","journal-title":"Gastroenterology"},{"key":"67_CR59","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1023\/A:1026673811278","volume":"44","author":"P Angulo","year":"1999","unstructured":"Angulo P, Bharucha AE, Jorgensen RA, et al.: Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999, 44:602\u2013607.","journal-title":"Dig Dis Sci"},{"key":"67_CR60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1013240225965","volume":"47","author":"P Angulo","year":"2002","unstructured":"Angulo P, MacCarty RL, Sylvestre PB, et al.: Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002, 47:157\u2013161.","journal-title":"Dig Dis Sci"},{"key":"67_CR61","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0002-9270(00)01059-5","volume":"95","author":"HJ Hoogstraten van","year":"2000","unstructured":"van HoogstratenHJ, Vleggaar FP, Boland GJ, et al.: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000, 95:2015\u20132022.","journal-title":"Am J Gastroenterol"},{"key":"67_CR62","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","volume":"95","author":"P Angulo","year":"2000","unstructured":"Angulo P, Batts KP, Jorgensen RA, et al.: Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2333\u20132337.","journal-title":"Am J Gastroenterol"},{"key":"67_CR63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004836-200012000-00005","volume":"31","author":"A Duchini","year":"2000","unstructured":"Duchini A, Younossi ZM, Saven A, et al.: An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000, 31:292\u2013296.","journal-title":"J Clin Gastroenterol"},{"key":"67_CR64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.mcg.0000177230.13770.4e","volume":"39","author":"JA Talwalkar","year":"2005","unstructured":"Talwalkar JA, Angulo P, Keach JC, et al.: Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005, 39:168\u2013171.","journal-title":"J Clin Gastroenterol"},{"key":"67_CR65","doi-asserted-by":"crossref","unstructured":"Chen W, Gluud C: Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2004, (3):CD004036.","DOI":"10.1002\/14651858.CD004036.pub2"},{"key":"67_CR66","first-page":"455","volume":"90","author":"DH Thiel Van","year":"1995","unstructured":"Van Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455\u2013459.","journal-title":"Am J Gastroenterol"},{"key":"67_CR67","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-131-12-199912210-00006","volume":"131","author":"C Schramm","year":"1999","unstructured":"Schramm C, Schirmacher P, Helmreich-Becker I, et al.: Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999, 131:943\u2013946.","journal-title":"Ann Intern Med"},{"key":"67_CR68","first-page":"57","volume":"86","author":"KD Lindor","year":"1991","unstructured":"Lindor KD, Wiesner RH, Colwell LJ, et al.: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 86:57\u201361.","journal-title":"Am J Gastroenterol"},{"key":"67_CR69","first-page":"511","volume":"91","author":"KD Lindor","year":"1996","unstructured":"Lindor KD, Jorgensen RA, Anderson ML, et al.: Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996, 91:511\u2013515.","journal-title":"Am J Gastroenterol"},{"key":"67_CR70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2036.2004.02214.x","volume":"20","author":"RK Sterling","year":"2004","unstructured":"Sterling RK, Salvatori JJ, Luketic VA, et al.: A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004, 20:943\u2013949.","journal-title":"Aliment Pharmacol Ther"},{"key":"67_CR71","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","volume":"40","author":"M Farkkila","year":"2004","unstructured":"Farkkila M, Karvonen AL, Nurmi H, et al.: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40:1379\u20131386.","journal-title":"Hepatology"},{"key":"67_CR72","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/00365520310006009","volume":"38","author":"B Brandsaeter","year":"2003","unstructured":"Brandsaeter B, Friman S, Broome U, et al.: Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003, 38:1176\u20131183.","journal-title":"Scand J Gastroenterol"},{"key":"67_CR73","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(02)11861-7","volume":"360","author":"A Vera","year":"2002","unstructured":"Vera A, Moledina S, Gunson B, et al.: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002, 360:1943\u20131944.","journal-title":"Lancet"},{"key":"67_CR74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/jlts.2003.50143","volume":"9","author":"M Kugelmas","year":"2003","unstructured":"Kugelmas M, Spiegelman P, Osgood MJ, et al.: Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003, 9:727\u2013732.","journal-title":"Liver Transpl"},{"key":"67_CR75","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1572-0241.2004.04050.x","volume":"99","author":"A Maheshwari","year":"2004","unstructured":"MaheshwariA, Yoo HY, Thuluvath PJ: Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004, 99:538\u2013542. Based on this study using the UNOS database, the authors do not recommend preemptive liver transplantation for patients with PSC.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-006-0067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-006-0067-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-006-0067-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:03:57Z","timestamp":1559433837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-006-0067-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s11894-006-0067-8","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}